Welcome to the first issue of the Orphan Disease Center Newsletter!

The Orphan Disease Center (ODC) was created to accelerate and expand upon the orphan disease research activities already underway in our community. Building on the legacy of translational research at Penn, the ODC focuses on the development of novel treatments for rare diseases. Our success is predicated on three basic principles: innovation, partnership and execution. Therapies based on small molecules and gene therapy vectors developed in Penn laboratories are showing tremendous promise in the clinic.

I am honored to have served as the ODC director for the past two years, as it gives me the privilege of bearing witness to a transformation process in the diagnosis and treatment of rare diseases. This is only the beginning of a revolution in the practice of medicine that will play out in the laboratories and clinics at Penn. We are proud to share a small portion of that work with you in this newsletter.

Sincerely,

James M. Wilson, MD, PhD

Our Mission

Orphan diseases represent a collection of disorders that affect fewer than 200,000 individuals for any single disease type, yet there are more than 7,000 distinct orphan diseases. In the aggregate, more than 25 million people in the United States suffer substantial morbidity and mortality from orphan diseases. Despite this huge number, research in most disease types has lagged far behind other major areas due to a combination of technological and funding limitations.

The Orphan Disease Center will develop transformative therapies through use of platform technologies and development of research strategies that can be deployed across multiple rare diseases. We will emphasize disorders with substantial unmet need, independent of their incidence and will strive to assure access to patients of all populations.

WHAT IS AN Orphan Disease?

An orphan (rare) disease is defined in the United States as one that affects fewer than 200,000 people.

About 50% affected are children and about 30% of them will only live to be 5 years of age.

There are approximately 7,000 different rare diseases, affecting 350 million people worldwide and 30 million in the United States alone (that’s 1 in 10 Americans).

We serve the purpose of making science and research accessible to rare diseases.
Orphan Disease Center Groundbreaking Achievements and Milestones

Penn scientists from the ODC have made huge strides toward our goal of treating and potentially curing rare diseases. The team is delighted to share with you some of these accomplishments:

1. **Jean Bennett, MD, PhD** and **Al Maguire, MD** from the Center for Advanced Retinal and Ocular Therapeutics continue their pioneering work on gene therapy for inherited blindness. In collaboration with a local biotechnology company called SPARK Therapeutics, they have advanced a gene therapy trial for the treatment of a form of congenital blindness into phase III, which is likely to be the first FDA-approved gene therapy in the United States.

2. Gene therapy vectors discovered in the laboratory of **James Wilson, MD, PhD** have become the industry standard for in vivo gene therapy for rare diseases. This technology has been licensed to more than 10 companies and is in research and development in 28 diseases. Some spectacular results have already been achieved in patients with hemophilia B and spinal muscular atrophy.

3. **Dan Rader, MD** from the Department of Genetics has developed a number of novel treatments for rare, inherited forms of hypercholesterolemia. His group developed the preclinical and clinical proof-of-concept data for a small molecule drug, lomitapide, which received FDA approval for treating these orphan diseases. Dr. Rader will soon be enrolling patients with this same disease in a clinical trial based on permanent correction of the disease using gene therapy.

ODC Programs

**Programs of Excellence**

Based on the existing strengths within the Penn and CHOP communities, we have identified eight Programs of Excellence for the Center. Each program is designed to further the mission of the ODC, and we anticipate that more programs will be added as the Center evolves.

- Inherited Blindness
- Liver Metabolic Disorders
- Neurologic and Muscle Diseases
- Lysosomal Storage and Related Diseases
- Pulmonary Diseases
- Mucopolysaccharidoses
- CDKL5 Deficiency
- Motor Neuron Diseases

**Symposia**

The ODC hosts several scientific symposia throughout the year focused on different areas of rare disease research and therapy, bringing together key opinion leaders from academia, patient foundations and the pharmaceutical industry. Since 2015, the ODC has hosted symposia on the following:

- Castleman Disease
- Cystic Fibrosis
- Lymphangioleiomyomatosis
- Duchenne Muscular Dystrophy
- Crigler-Najjar Syndrome
- Spinal Muscular Atrophy
- Angelman Syndrome

**Grant Programs**

The ODC proudly supports five pilot grant programs in the following areas:

- Mucopolysaccharidosis I
- Million Dollar Bike Ride (27 diseases)
- High-Throughput Screening Core
- CDKL5 Deficiency
- Genome Editing
Patient Spotlight: On the Other Side of Fear Is Joy

“It’s like a huge giant is squeezing you and just before you pop, he lets go,” Iesha says, describing the pain associated with having Sickle Cell Anemia (SCD). “And then he grabs you again and squeezes harder. You can’t move; you don’t want to even breathe because these actions will make everything worse. You’re at the whim of this giant as he squeezes you and squeezes you.”

This level of pain, called a “sickle cell crisis,” sends Iesha straight to an extended stay at the hospital, where her doctors work to bring her pain back to a manageable level.

“Having Sickle Cell Anemia has taught me not to be afraid. It has taught me that on the other side of fear is joy. There’s nothing but complete bliss after you get over your fear.”
— Iesha

Still, despite these regular bouts with tremendous pain, Iesha says that she thinks of herself as a “blessed” individual when it comes to having SCD.

“I’m only in the hospital once or twice a year,” she explains. “Other people are hospitalized much more often.”

Having lived with this disease her whole life, Iesha is level-headed and practical about how she deals with the debilitation brought on by a crisis. “I know what I need to be comfortable,” she says. “I always have to have my blanket, my laptop, my heat pack and my books from school. I’m immediately in communication with my professors to let them know I’m in the hospital. Some of them don’t like for me to do work then, but I try to get done what I can.” Now in her senior year at Southern Connecticut State University studying political science, Iesha says that her experience of balancing her condition with being a student has been mostly a positive one—unlike her childhood, where things were much more challenging.

“Elementary school and high school were really hard,” she says, looking down at her hands folded neatly in her lap. As a child, Iesha stood out as being different from the other kids. “I couldn’t participate in gym because I was short of breath. No one wanted me on their team,” she recalls. “It was not a nice feeling. The kids didn’t understand why I was always missing school. But I kept my condition a secret, because I didn’t want them to judge me.” Iesha has an older brother who also has SCD, but they both kept the disease very private and shared the weight of it only with immediate family, most particularly their mother. “My mom was always with me,” Iesha says. “It was often just me and her in the hospital.” Her eyes fill with tears, remembering. “Times when I almost died, and my mom was shocked. I didn’t realize that this disease was something that people might...” She pauses, looking for words, moving her hand to her heart. “A disease that people might come toward. I thought it was just something that people pushed away.”

Then, when Iesha was 15, one of her nurses started an SCD support group for teens. Meeting others with her condition was a huge turning point for Iesha. “For the first time, I met other people like me. They shared how their friends knew about their condition, their school knew. And I was like WHAT? Everyone KNOWS? I was shocked. I didn’t realize that this disease was something that people might...” She pauses, looking for words, moving her hand to her heart. “A disease that people might come toward. I thought it was just something that people pushed away.”

ODC Steering Committee

Jonathan A. Epstein, MD
William Wikoff Smith Professor Executive Vice Dean and Chief Scientific Officer Perelman School of Medicine, University of Pennsylvania

Glen N. Gaulton, PhD
Professor of Pathology and Laboratory Medicine Vice Dean and Director, Center for Global Health PSOM, University of Pennsylvania

Kevin B. Mahoney
Executive Vice President, University of Pennsylvania Health System Executive Vice Dean, Perelman School of Medicine Perelman Center for Advanced Medicine

Michael S. Parmacek, MD
Frank Wister Thomas Professor of Medicine Chair, Department of Medicine PSOM, University of Pennsylvania

Daniel J. Rader, MD (Chair)
Seymour Gray Professor of Molecular Medicine; Chair, Department of Genetics Chief, Division of Translational Medicine and Human Genetics, Department of Medicine, PSOM, UPenn Chief, Division of Human Genetics in Pediatrics, CHOP

Joseph W. St. Geme, III, MD
Leonard and Madlyn Abramson Professor of Pediatrics and Microbiology Physician-in-Chief and Chair, Department of Pediatrics, CHOP Chair, Department of Pediatrics, PSOM, University of Pennsylvania

Bryan A. Wolf, MD, PhD
Executive Vice-President and Chief Scientific Officer, CHOP Edmond F. Notebaert Endowed Chair in Pediatric Research, CHOP Professor of Pathology and Laboratory Medicine, PSOM, University of Pennsylvania

ODC External Advisory Committee

Arthur L. Caplan, PhD
Drs. William F and Virginia Connolly Mitty Chair Director, Division of Medical Ethics NYU Langone Medical Center

John F. Crowley
Chairman & CEO, Amicus Therapeutics

Stephen L. Eck, MD, PhD
Chairman & CEO, Amicus Therapeutics

Orphan Disease Center Staff

James M. Wilson, MD, PhD
Rose H. Weiss Professor and Director, Orphan Disease Center Professor of Medicine and Pediatrics, University of Pennsylvania wilsonjm@upenn.edu

Monique R. Molloy
Executive Director monique@upenn.edu

Samantha Charleston
Assistant Director scharle@upenn.edu

David Fajgenbaum, MD, MBA, MSc
Associate Director, Patient Impact dafidfa@upenn.edu

Ashley Winslow, PhD
Senior Director, Translational Research awinslow@upenn.edu


The Penn Medicine Orphan Disease Center Invites You to the 4th Annual Million Dollar Bike Ride

2016 MDBR In Review

$3,500,000 in 3 years

100% of all money raised directly funds rare disease research (no administrative cut).

600+ participants

27 rare disease teams

from 30 states

riding 17,538 miles

2017 MDBR:
Registration is Open!

When? Saturday, May 20, 2017 (Start 7:30 a.m.)
Where? Highline Park (31st St. and Chestnut)
Routes: 13, 34 and 72 mile options
Register: Contact Samantha Charleston (scharle@upenn.edu) or visit www.milliondollarbikeride.org.

Twitter: @MDBRide4Rare
Facebook: The Million Dollar Bike Ride for Orphan Disease Research
Instagram: @MDBRide4Rare
MDBR Website: www.milliondollarbikeride.org
ODC website: www.med.upenn.edu/orphandisease/